These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 38892306)

  • 41. Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics.
    Alhadrami HA; Sayed AM; Sharif AM; Azhar EI; Rateb ME
    Molecules; 2021 May; 26(9):. PubMed ID: 34062737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
    J A; Francis D; C S S; K G A; C S; Variyar EJ
    J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
    Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
    Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M
    Arutyunova E; Khan MB; Fischer C; Lu J; Lamer T; Vuong W; van Belkum MJ; McKay RT; Tyrrell DL; Vederas JC; Young HS; Lemieux MJ
    J Mol Biol; 2021 Jun; 433(13):167003. PubMed ID: 33895266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Searching possible SARS-CoV-2 main protease inhibitors in constituents from herbal medicines using
    Rasul HO; Thomas NV; Ghafour DD; Aziz BK; Salgado M G; Mendoza-Huizar LH; Candia LG
    J Biomol Struct Dyn; 2024 May; 42(8):4234-4248. PubMed ID: 37349945
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of Covalent Lead Compounds Targeting 3CL Protease with a Lateral Interactions Spiking Neural Network.
    Gu Z; Yan Y; Liu H; Wu D; Yao H; Lin K; Li X
    J Chem Inf Model; 2024 Apr; 64(8):3047-3058. PubMed ID: 38520328
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
    Dou X; Sun Q; Xu G; Liu Y; Zhang C; Wang B; Lu Y; Guo Z; Su L; Huo T; Zhao X; Wang C; Yu Z; Song S; Zhang L; Liu Z; Lai L; Jiao N
    Eur J Med Chem; 2022 Aug; 238():114508. PubMed ID: 35688005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In silico screening of potential inhibitors from Cordyceps species against SARS-CoV-2 main protease.
    Deshmukh N; Talkal R; Lakshmi B
    J Biomol Struct Dyn; 2024 Jun; 42(9):4395-4411. PubMed ID: 37325819
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
    Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
    Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An ISG15-Based High-Throughput Screening Assay for Identification and Characterization of SARS-CoV-2 Inhibitors Targeting Papain-like Protease.
    Samrat SK; Kumar P; Liu Y; Chen K; Lee H; Li Z; Chen Y; Li H
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205213
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
    Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
    J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor.
    Jiang Y; Wu Y; Wang J; Ma Y; Yu H; Wang Z
    Curr Med Chem; 2024; 31(38):6204-6226. PubMed ID: 38529602
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery and characterization of naturally occurring covalent inhibitors of SARS-CoV-2 M
    Hu Q; Zhang Y; Chen P; Zhang Y; Zhu G; Liu W; Wang C; Zheng S; Shen N; Wang H; Huang P; Ge G
    Chin J Nat Med; 2024 Sep; 22(9):797-807. PubMed ID: 39326974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M
    Mercorelli B; Desantis J; Celegato M; Bazzacco A; Siragusa L; Benedetti P; Eleuteri M; Croci F; Cruciani G; Goracci L; Loregian A
    Antiviral Res; 2022 Aug; 204():105350. PubMed ID: 35688349
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
    J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.
    Lee JY; Kuo CJ; Shin JS; Jung E; Liang PH; Jung YS
    Bioorg Med Chem Lett; 2021 Jun; 42():128067. PubMed ID: 33957246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.